modelS02AA17
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Fosfomycin | |
| ATC code: | S02AA17 | route: | oral |
| compartments: | 1 | |
| dosage: | 3000 | mg |
| volume of distribution: | 16.3 | L |
| clearance: | 6.06 | L/h |
| other parameters in model implementation | ||
Fosfomycin is a broad-spectrum antibiotic, primarily active against Gram-negative and some Gram-positive bacteria. It is commonly used for the treatment of uncomplicated urinary tract infections, especially due to its oral availability and good safety profile. Fosfomycin trometamol is approved and widely used in the management of acute cystitis. Other formulations are used intravenously for systemic infections.
Pharmacokinetics
Single dose pharmacokinetics in healthy adult volunteers following oral fosfomycin trometamol administration.
References
Isla, A, et al., & Rodríguez-Gascón, A (2024). Population pharmacokinetics of oral fosfomycin calcium in healthy women. The Journal of antimicrobial chemotherapy 79(11) 2837–2845. DOI:10.1093/jac/dkae295 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39205651
Kane, Z, et al., & Standing, JF (2021). IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis. The Journal of antimicrobial chemotherapy 76(7) 1855–1864. DOI:10.1093/jac/dkab083 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33855449
Wenzler, E, et al., & Rodvold, KA (2017). Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers. Antimicrobial agents and chemotherapy 61(9) –. DOI:10.1128/AAC.00775-17 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28630194
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)